Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD3632 in Advanced Haematologic Malignancies (MOMENTUM)
NCT07155226Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2026
- Primary completion
- Feb 2029
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of AZD3632 in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), sponsored by AstraZeneca. Started Jan 2026; status: recruiting.
02
Drugs
AZD3632
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT07155226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07155226.